3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Interventions
Rituximab
88
Cyclophosphamide
81
Prednisone
48
Doxorubicin
44
Lenalidomide
37
Vincristine
35
polatuzumab vedotin
29
Magnetic Resonance Spectroscopy
29
Gemcitabine
27
Etoposide
26
Specimen Handling
25
fludarabine
23
Biopsy
21
Oxaliplatin
20
CT-P10
20
glofitamab
17
tafasitamab
15
obinutuzumab
15
ibrutinib
14
zanubrutinib
13
fludarabine phosphate
13
pembrolizumab
12
axicabtagene ciloleucel
12
Immunotherapy, Adoptive
12
Ifosfamide
12
venetoclax
11
deltacortene
11
prednylidene
10
Prednisolone
10
Leukapheresis
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Inotuzumab Ozogamicin
×
1 year
×
Clear all
NCT01679119
2026-04-07
INCA
University College, London
Phase 2
Completed
129 enrolled
7 charts